Donald Milligan

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Alan K. Burnett, Robert K. Hills, Donald Milligan et al. · Journal of Clinical Oncology · 2010 · 652 citations · Full text

Medicine, Oncology, Pharmacology +17

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

Peter J. Campbell, Linda M. Scott, Georgina Buck et al. · The Lancet · 2005 · 645 citations

Medicine, Genetics, Hematology +13

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Alan K. Burnett, Donald Milligan, Archie Prentice et al. · Cancer · 2007 · 616 citations · Full text

Medicine, Oncology, Pharmacology +13

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Panagiotis Kottaridis, Donald Milligan, Rajesh Chopra et al. · Blood · 2000 · 502 citations

Life Sciences, Cell Biology, Immunology +14

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

Animesh Pardanani, Claire Harrison, Jörge E. Cortes et al. · JAMA Oncology · 2015 · 472 citations

Medicine, Hematology, Pharmacology +14